Last reviewed · How we verify

EPOETIN DELTA

FDA-approved approved Recombinant protein ✓ Verified May 2026 Quality 2/100

EPOETIN DELTA is a drug. It is currently FDA-approved (first approved 2002).

Epoetin delta, also known as Dynepo, is a protein-based erythropoietin receptor agonist used to treat conditions such as anemia and chronic kidney diseases. It works by stimulating the erythropoietin receptor to increase red blood cell production.

At a glance

Generic nameEPOETIN DELTA
ModalityRecombinant protein
PhaseFDA-approved
First approval2002

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
FDA labelMechanism, indications, dosing, boxed warnings, drug interactions
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about EPOETIN DELTA

What is EPOETIN DELTA?

EPOETIN DELTA is a Recombinant protein drug.

When was EPOETIN DELTA approved?

EPOETIN DELTA was first approved on 2002.

What development phase is EPOETIN DELTA in?

EPOETIN DELTA is FDA-approved (marketed).

Related

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing